5 Must-Read Analyst Questions From Universal Health Services's Q3 Earnings Call

By Anthony Lee | November 03, 2025, 12:32 AM

UHS Cover Image

Universal Health Services posted third quarter results that exceeded Wall Street’s expectations, leading to a significant positive market reaction. Management attributed this performance to robust acute care hospital activity, improved pricing in both core segments, and the financial benefit from a supplemental Medicaid program in the District of Columbia. CEO Marc Miller specifically highlighted progress at newly opened hospitals in Nevada and Washington, D.C., and noted that operational efficiency and expense management further supported profitability. CFO Steve Filton pointed to a 2% increase in acute care admissions and growth in both inpatient and outpatient services as key factors.

Is now the time to buy UHS? Find out in our full research report (it’s free for active Edge members).

Universal Health Services (UHS) Q3 CY2025 Highlights:

  • Revenue: $4.50 billion vs analyst estimates of $4.37 billion (13.4% year-on-year growth, 2.8% beat)
  • Adjusted EPS: $5.69 vs analyst estimates of $4.95 (14.9% beat)
  • Adjusted EBITDA: $676.7 million vs analyst estimates of $611.5 million (15.1% margin, 10.7% beat)
  • The company slightly lifted its revenue guidance for the full year to $17.38 billion at the midpoint from $17.2 billion
  • Management raised its full-year Adjusted EPS guidance to $21.80 at the midpoint, a 9% increase
  • EBITDA guidance for the full year is $2.59 billion at the midpoint, above analyst estimates of $2.54 billion
  • Operating Margin: 11.6%, up from 9.7% in the same quarter last year
  • Same-Store Sales rose 2% year on year, in line with the same quarter last year
  • Market Capitalization: $13.81 billion

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Universal Health Services’s Q3 Earnings Call

  • Justin Lake (Wolfe Research) asked about pending Medicaid supplemental payments in Florida and Nevada; CFO Steve Filton detailed potential benefits totaling $75–80 million, emphasizing both programs still require regulatory approval.
  • Jason Cassorla (Guggenheim) questioned the drivers behind updated full-year guidance; Filton broke down the impact of D.C. Medicaid payments, malpractice reserves, and legal settlements, noting that core business trends are expected to remain stable.
  • Ben Hendrix (RBC Capital Markets) inquired about surgical volume trends and case mix; Filton responded that surgical procedure volumes improved slightly year-over-year, with cardiology services showing particular strength.
  • Raj Kumar (Stephens) pressed on behavioral health labor trends and volume growth; Filton outlined persistent but improving staffing issues, highlighting that additional hiring should support future patient day growth and outpatient expansion.
  • Kevin Fischbeck (Bank of America) explored competitive dynamics in behavioral health and the company’s outpatient strategy; Filton and Marc Miller explained that focused reorganization and dedicated outpatient staffing are expected to drive incremental volume and market share.

Catalysts in Upcoming Quarters

Looking ahead, our team will watch (1) the ramp-up and profitability at recently opened hospitals, (2) further progress in hiring and capacity utilization within behavioral health, and (3) the rollout and early performance of new outpatient access points—both in acute and behavioral segments. Developments in Medicaid supplemental payment approvals and payer contract negotiations will also be critical.

Universal Health Services currently trades at $220.32, up from $214.06 just before the earnings. Is there an opportunity in the stock?See for yourself in our full research report (it’s free for active Edge members).

The Best Stocks for High-Quality Investors

Donald Trump’s April 2025 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities.

The smart money is already positioning for the next leg up. Don’t miss out on the recovery - check out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.

Latest News